In June 2017 the General Health Law was amended to permit the following cannabis-related activities to be undertaken in Mexico:
- research protocols regarding pharmaceuticals which contain a cannabis derivative; and
- approvals of pharmaceuticals which contain a cannabis derivative, including tetrahydrocannabinol (THC).
In addition, the law was amended to permit the production of industrial products with a THC content of less than 1%.
On 30 October 2018 the former commissioner of the Federal Commission for the Protection against Sanitary Risk issued guidelines and granted permits for 38 industrial products with a THC content of less than 1%. No additional permits have been issued by the new administration, which took office on 1 December 2018.
However, the Ministry of Health recently announced that:
- the 30 October 2018 guidelines have been suspended;
- all permits granted under the suspended guidelines will be reviewed; and
- new draft regulations will be prepared in coordination with the Ministry of the Interior.
For further information on this topic please contact José Alberto Campos Vargas or Juan Luis Serrano-Leets at Sanchez-DeVanny Eseverri SC by telephone (+52 55 5029 8500) or email ([email protected] or [email protected]). The Sanchez-DeVanny Eseverri SC website can be accessed at www.sanchezdevanny.com.
This article was first published by the International Law Office, a premium online legal update service for major companies and law firms worldwide. Register for a free subscription.
